Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03697109 · OUTCOME

Change in SBP and DBP During the RW Phase

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome · Source last updated 2025-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
LEAST_SQUARES_MEAN
Unit
mm Hg
Interval / dispersion
95% Confidence Interval
Time frame
Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)

What was measured

Blood pressure was measured by 24-hour ABPM.

Analysis population: The analysis population was patients in the ITT-RW Population who had HTN with or without DM/IGT at Baseline.

Groups in this outcome

Relacorilant (RW Phase)

Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase. Relacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.

Placebo (RW Phase)

Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug. Placebo: Placebo matched to study drug

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Relacorilant (RW Phase)21
Placebo (RW Phase)22

Reported measurements

SBP
Values in mm Hg · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Relacorilant (RW Phase)3.95Not reported0.4707.424Not reported
Placebo (RW Phase)10.43Not reported6.53814.329Not reported
DBP
Values in mm Hg · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Relacorilant (RW Phase)2.86Not reported-0.1995.928Not reported
Placebo (RW Phase)6.53Not reported3.2249.832Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.470
        upper Limit
        7.424
        value
        3.95
      2. group Id
        OG001
        lower Limit
        6.538
        upper Limit
        14.329
        value
        10.43
    title
    SBP
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -0.199
        upper Limit
        5.928
        value
        2.86
      2. group Id
        OG001
        lower Limit
        3.224
        upper Limit
        9.832
        value
        6.53
    title
    DBP
denoms
  1. counts
    1. group Id
      OG000
      value
      21
    2. group Id
      OG001
      value
      22
    units
    Participants
description
Blood pressure was measured by 24-hour ABPM.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase. Relacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.
    id
    OG000
    title
    Relacorilant (RW Phase)
  2. description
    Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug. Placebo: Placebo matched to study drug
    id
    OG001
    title
    Placebo (RW Phase)
param Type
LEAST_SQUARES_MEAN
population Description
The analysis population was patients in the ITT-RW Population who had HTN with or without DM/IGT at Baseline.
reporting Status
POSTED
time Frame
Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)
title
Change in SBP and DBP During the RW Phase
type
SECONDARY
unit Of Measure
mm Hg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice